Deal Overview On May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business ...
Medtronic announced a spin-off of its diabetes business in May, which will be completed in 2026 and be immediately accretive to its EPS, operating, and gross margins. The spin-off will enable the ...
Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback